Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO045 in Duchenne Muscular Dystrophy
NCT01826474Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jan 2013
- Primary completion
- Aug 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 2 trial of PRO-045 in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical. Started Jan 2013; status: terminated.
02
Drugs
PRO-045
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01826474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01826474.